Friday, March 20, 2020

08:15–08:30 Welcome

SESSION I – The genomic and epigenomic landscape of CLL and clinical consequences
Chair (s): TBA

08:30-08:45 Genetic predisposition
Jennifer Brown (Boston)
08:45-08:50 Discussion

08:50-09:05 Genetic landscape
Cathy Wu (Boston)
09:05-09:10 Discussion

09:10-09:25 Ibrutinib
Jennifer Woyach (Colombus)
09:25-09:30 Discussion

09:30-09:45 Epigenetic landscape
Christopher Oakes (Columbus)
09:45-09:50 Discussion

09:50-10:05 Risk stratification in CLL: future perspective with focus on complex karyotype and NOTCH1 mutations
Panagiotis Baliakas (Uppsala)
10:05-10:10 Discussion

10:10-10:40 Panel discussion

10:40-11:10 Coffee Break

SESSION II – The role of BCR activation and signalling for CLL
Chair (s): TBA

11:10-11:25 BCR isotypes/autonomous signalling
Hassan Jumaa (Ulm)
11:25-11:30 Discussion

11:30-11:45 The latest news on stereotypes
Kostas Stamatopoulos (Thessaloniki)
11:45-11:50 Discussion

11:50-12:05 Novel BCR targets
Andrew Steele (Southampton)
12:05-12:10 Discussion

Draft program subject to change 11/02/2020
12:10-12:25  Next generation BTK inhibitors (covalent/non-covalent?)  Anthony Mato (New York)
12:25-12:30  Discussion

**SHORT ORAL COMMUNICATION**

12:30-12:37  *Mutational landscape of CLL mice models overexpressing aid identify proliferative-associated tumor genes involved in leukemic progression*  Pablo Oppezzo (Montevideo)
12:37-12:40  Discussion

12:40-13:10  Panel discussion

13:10-14:50  Lunch

**13:30-14:30 SATELLITE SYMPOSIUM:**
**Utilization of MRD assessment in the clinical management of CLL patients**

*Chair: Barbara Eichhorst (Cologne)*
*Speakers: Barbara Eichhorst (Cologne), Lanny Kirsch (Seattle), Anna Schuh (Oxford)*

*This symposium is organised and funded by Adaptive Biotechnologies.*

**SESSION III – Therapeutic options for CLL**
*Chair(s): TBA*

14:50-15:05  Ibrutinib for everybody  Jennifer Woyach (Columbus)
15:05-15:10  Discussion

15:10-15:25  Ibrutinib for a small subgroups only  Florence Cymbalista (Bobigny)
15:25-15:30  Discussion

15:30-15:45  MURANO and MRD  John Seymour (Melbourne)
15:45-15:50  Discussion

15:50-16:05  CLL14 update  Kirsten Fischer (Cologne)
16:05-16:10  Discussion

**SHORT ORAL COMMUNICATION**

16:10-16:17  *Neddylation pathway regulates treg differentiation and T-cell function in Chronic Lymphocytic Leukemia ex vivo and murine in vivo studies*  Scott Best (Portland)
16:17-16:20  Discussion

16:20-16:50  Panel discussion

16:50-17:20  Coffee break

**SESSION IV – Long term follow up of clinical trials versus real world data (Outside Clinical Trials data-OCT)**
*Chair (s): TBA*

17:20-17:35  Ibrutinib trials  Alessandra Tedeschi (Milan)
17:35-17:40  Discussion
17:40-17:55  Ibrutinib real world  George Follows (Cambridge)
17:55-18:00  Discussion

18:00-18:15  Venetoclax trials  Matthew Davids (Boston)
18:15-18:20  Discussion

18:20-18:35  Venetoclax / PI3K real world  Anthony Mato (New York)
18:35-18:40  Discussion

**SHORT ORAL COMMUNICATION**

18:40-18:47  Sequential treatment with bendamustine, obinutuzumab (GA101) and ibrutinib in Chronic Lymphocytic Leukemia: final results of the CLL2-BIG trial of the German CLL study group (GCLLSG)  Julie von Tresckow (Cologne)
18:47-18:50  Discussion

18:50-19:20  Panel discussion

19:20  *Get together and poster walks (stand up cocktails and buffet dinner for all)*

---

**Saturday, March 21, 2020**

09:00-10:00  Possible slot for a satellite symposium

09:00-10:00  3 Simultaneous Meet the Expert sessions (non-clinical)

1.  Prognostic and predictive markers  Barbara Eichhorst (Cologne)
2.  Resistance to ibrutinib: what to do  Jennifer Brown (Boston)
3.  First line therapy: continuous or time limited treatment?  Michael Hallek (Cologne)

10:00-10:30  Coffee break

**SESSION V – The increasing role of the leukaemic microenvironment**

*Chair (s): TBA*

10:30-10:45  Role of stromal cells  Andrea Brendolan (Milan)
10:45-10:50  Discussion

10:50-11:05  Hypoxia, metabolic reprogramming and immunosuppression occurring in CLL niche  Silvia Deaglio (Turin)
11:05-11:10  Discussion

11:10-11:25  Role of T cells  Arnon Kater (Amsterdam)
11:25-11:30  Discussion

11:30-11:45  Immunomodulatory effects of kinase inhibitors  Adrian Wiestner (Bethesda)
11:45-11:50  Discussion

**SHORT ORAL COMMUNICATION**

11:50-11:57  Expansion of antitumor cytotoxic CD8+ T cells in CLL patients treated with ibrutinib  Maria Joao Baptista (Badalona)
11:57-12:00  Discussion
12:00-12:30  Panel discussion

12:30-14:10  Lunch

13:00-14:00  Possible slot for a satellite symposium

SESSION VI – Therapeutic options 2: The use of cellular and non-cellular immunotherapies in CLL
Chair (s): TBA

14:10-14:25  Next generation PI3K inhibitors  
Peter Hillmen (Leeds)

14:25-14:30  Discussion

14:30-14:45  Novel inhibitors at preclinical level  
(MCL1 & CDK inhibitors)  
Alexey Danilov (Los Angeles)

14:45-14:50  Discussion

14:50-15:05  Mechanistic effects of BH3 Mimetics in CLL  
Eric Eldering (Amsterdam)

15:05-15:10  Discussion

15:10-15:25  CAR-T cells  
David Maloney (Seattle)

15:25-15:30  Discussion

15:30-15:45  Allo-transplant  
Peter Dreger (Heidelberg)

15:45-15:50  Discussion

15:50-16:20  Panel discussion

16:20-16:50  Coffee break

SESSION VII – Efficacy through safety
Chair (s): TBA

16:50-17:05  Cardiologist  
Javid Moslehi (Nashville)

17:05-17:10  Discussion

17:10-17:25  Dermatologist  
Nicole LeBoeuf (Boston)

17:25-17:30  Discussion

17:30-17:45  Infectious diseases  
Pierluigi Viale (Bologna)

17:45-17:50  Discussion

17:50-18:05  Gastroenterology  
Stefano Fagiuoli (Bergamo)

18:05-18:10  Discussion

18:10-18:40  Panel discussion

Free evening

Sunday, March 22, 2020

07:30-08:30  3 Simultaneous Breakfast Meet the Expert Sessions (clinical)

1. Treatment of relapsed CLL  
   Paolo Ghia (Milan)

2. Management of novel drugs side effect  
   Carol Moreno (Barcelona)

3. MRD assessment  
   Andrew Rawstron (Leeds)
SESSION VIII – Clonal heterogeneity, clonal evolution and mechanisms of drug resistance
Chair (s): TBA

08:40-08:55  Clonal evolution  Davide Rossi (Bellinzona)
08:55-09:00  Discussion

09:00-09:15  PI3K  Jennifer Brown (Boston)
09:15-09:20  Discussion

09:20-09:35  Venetoclax  John Seymour (Melbourne)
09:35-09:40  Discussion

SHORT ORAL COMMUNICATIONS

09:40-09:47  Aid-mediated mechanisms of resistance to BCR inhibitors in Chronic Lymphocytic Leukemia (CLL)  Chiara Pighi (Turin)
09:47-09:50  Discussion

09:50-09:57  NOTCH2 contributes to venetoclax resistance in Chronic Lymphocytic Leukemia  Stefania Fiorcari (Modena)
09:57-10:00  Discussion

10:00-10:30  Panel discussion

10:30-11:00  Coffee break

SESSION IX – Contrasting therapeutic concepts:
Chair (s): TBA

11:00-11:15  MRD as a dynamic endpoint  Peter Hillmen (Leeds)
11:15-11:20  Discussion

11:20-11:35  Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction in lymphoid malignancies including CLL  David M. Kurtz (Stanford)
11:35-11:40  Discussion

11:40-11:55  Sequential vs combination treatments  Bill Wierda (Houston)
11:55-12:00  Discussion

12:00-12:15  Time limited vs continuous treatments  Barbara Eichhorst (Cologne)
12:15-12:20  Discussion

12:20-12:50  Panel discussion

12:50-13:00  Closing Remarks

MEETING CLOSURE